Related Experiment Video
Updated: Mar 31, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression
Sajjad Hussain1, Tibor Bedekovics1, Marta Chesi2
1Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract:
The success of proteasome inhibition in multiple myeloma highlights the critical role for the ubiquitin-proteasome system (UPS) in this disease. However, there has been little progress in finding more specific targets within the UPS involved in myeloma pathogenesis. We previously found the ubiquitin hydrolase UCH-L1 to be frequently over-expressed in B-cell malignancies, including myeloma, and showed it to be a potent oncogene in mice. Here we show that UCH-L1 is a poor prognostic factor that is essential for the progression of myeloma. We found high levels of UCHL1 to predict early progression in newly diagnosed patients; a finding reversed by the inclusion of bortezomib. We also found high UCHL1 levels to be a critical factor in the superiority of bortezomib over high-dose dexamethasone in relapsed patients. High UCHL1 partially overlaps with, but is distinct from, known genetic risks including 4p16 rearrangement and 1q21 amplification. Using an orthotopic mouse model, we found UCH-L1 depletion delays myeloma dissemination and causes regression of established disease. We conclude that UCH-L1 is a biomarker of aggressive myeloma that may be an important marker of bortezomib response, and may itself be an effective target in disseminated disease.
Insights
Ubiquitin hydrolase UCH-L1 is overexpressed in multiple myeloma, acting as a poor prognostic factor. Targeting UCH-L1 may improve treatment outcomes for aggressive disease.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The ubiquitin-proteasome system (UPS) is crucial in multiple myeloma (MM).
- Specific UPS targets in MM pathogenesis remain largely unexplored.
- UCH-L1 (ubiquitin hydrolase-L1) is overexpressed in B-cell malignancies and acts as an oncogene.
Purpose of the Study:
- To investigate the prognostic significance of UCH-L1 in multiple myeloma.
- To determine UCH-L1's role in MM progression and response to therapy.
- To evaluate UCH-L1 as a potential therapeutic target in MM.
Main Methods:
- Analysis of UCH-L1 expression in newly diagnosed and relapsed multiple myeloma patients.
- Correlation of UCH-L1 levels with clinical outcomes and genetic risk factors.
- Assessment of UCH-L1's functional role using an orthotopic mouse model of MM.
Main Results:
- High UCH-L1 expression is a poor prognostic indicator for early progression in newly diagnosed MM patients.
- Bortezomib treatment reversed the negative prognostic impact of high UCH-L1.
- High UCH-L1 levels predicted bortezomib's superiority over dexamethasone in relapsed MM.
- UCH-L1 depletion delayed disease dissemination and induced regression in a mouse model.
- UCH-L1 expression is distinct from known genetic risks like 4p16 and 1q21 alterations.
Conclusions:
- UCH-L1 is a biomarker for aggressive multiple myeloma and a predictor of bortezomib response.
- UCH-L1 is essential for MM progression and may serve as a therapeutic target in disseminated disease.
